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Individualized Treatment Rules: Generating
Candidate Clinical Trials
Maya L. Petersen, Steven G. Deeks, and Mark J. van der Laan
Abstract
Statistical methods have rarely been applied to learn individualized treatment
rules, or rules for altering treatments over time in response to changes in indi-
vidual covariates. Termed dynamic treatment regimes in the statistical literature,
such individualized treatment rules are of primary importance in the practice of
clinical medicine. History-Adjusted Marginal Structural Models (HA-MSM) esti-
mate individualized treatment rules that assign, at each time point, the first action
of the future static treatment plan that optimizes expected outcome given a pa-
tient’s covariates. However, as we discuss here, the optimality of these rules can
depend on the way in which treatment was assigned in the data from which the
rules were derived. In this article we discuss the conditions sufficient for treatment
rules identified by HA-MSM to be statically optimal, or in other words, to select
the optimal future static treatment plan at each time point, regardless of the way in
which past treatment was assigned. The resulting treatment rules form appropri-
ate candidates for evaluation using randomized controlled trials. We demonstrate
that a history-adjusted individualized treatment rule is statically optimal if it de-
pends on a set of covariates that are sufficient to control for confounding of the
effect of past treatment history on outcome. Methods and results are illustrated
using an example drawn from the antiretroviral treatment of patients infected with
HIV. Specifically, we focus on rules for deciding when to modify the treatment of
patients infected with resistant virus.
 1
1. INTRODUCTION 
Many pressing clinical questions involve strategies or rules for deciding how 
treatments should be assigned and changed over time. To be effective, such strategies must 
be individualized. In other words, treatment must be assigned and modified in response to 
individual changes in disease progression, side effects, and other patient characteristics.  
Examples of such individualized treatment rules, known as dynamic treatment regimes in 
the statistical literature, include the decision to start anti-hypertensive medication in 
response to repeated measurements of hypertension and the decision to modify the dose of 
an antidepressant medication in response to adverse effects. Individualized treatment rules 
can be contrasted with static treatment regimens, in which treatment can change over time, 
but not in response to individual covariates.  An example of this would be the design of 
most current randomized controlled trials, in which participants are assigned to take a drug 
of interest for a specified time interval. However, despite the fact that individualized 
treatment rules, often in the form of clinical guidelines, are used ubiquitously in clinical 
care, such rules are rarely derived rigorously from data.  
Recent work has aimed to learn individualized treatment rules statistically. 
Structural nested mean models, presented by Murphy and Robins, aim to estimate dynamic 
regimes that optimize expected patient outcome [1, 2]. However, the programming 
required to implement these methods is substantial. In addition, this and related approaches 
estimate rules that optimize expected outcome at a fixed time point. Clinical practice, 
however, is often aimed at optimizing a moving target (e.g., a patient’s outcome 6 months 
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in the future). Perhaps for these reasons, in practice estimation of optimal dynamic 
treatment regimes remains rare. 
In this article, we present a novel statistical method for using observational data to 
estimate individualized treatment rules. Our method estimates rules that are not truly 
optimal among all dynamic rules (as estimated by Murphy, et. al.), but rather rules that are 
statically optimal [3]. As a result, our method can be implemented using standard software. 
We argue that static optimality is both an interpretable and interesting property, and point 
out several advantages of our approach compared to previous approaches aimed at 
estimating dynamic rules. 
Our method employs history-adjusted marginal structural models (HA-MSM) [3-
6], a generalization of the marginal structural model (MSM) approach to causal inference 
[5-8].  HA-MSM estimate individualized treatment rules by identifying, at each time point, 
the future static treatment plan that optimizes expected outcome given individual 
covariates of interest. The first action of this static plan is then assigned, and the optimal 
future static plan recalculated at the subsequent time point. The resulting treatment 
regimen is a dynamic rule, in that the treatment assigned can change in response to 
individual covariates [3, 4].   
However, as we explain, the treatment rules identified by HA-MSM can depend on 
the way in which treatment was assigned in the study population (the treatment 
mechanism). As a result, if these rules were applied at a given time point to an identical 
population in which treatment up till that time point had been assigned differently, they 
would not necessarily identify the future treatment plan that would optimize expected 
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outcome. In this paper, we present conditions sufficient to ensure that the treatment rule 
estimated by HA-MSM is truly “statically optimal”, or in other words, that the treatment 
rule identifies at each time point the first action of a static treatment regimen that is optimal 
regardless of treatment assignment up till that time point.  Using the directed acyclic graph 
(DAG) framework [9], we illustrate that specific causal structures are sufficient to ensure 
static optimality. Finally, we show that when these conditions are not met HA-MSM can 
still be used to derive statically optimal treatment rules, by incorporating a summary of 
patient history, such as that provided by the treatment mechanism, into the individualized 
rule. 
Throughout the article, we rely on an example drawn from the treatment of HIV 
infection: when antiretroviral therapy (ART) fails to completely suppress the virus, what 
treatment rule should be used to decide when to modify a patient’s regimen? In Section 2, 
we present some background on this clinical question and the data used to address it. (For a 
full description of the sample and corresponding HA-MSM models, see Petersen et. al. 
[4].) Section 3 uses this data example to review HA-MSM, including key assumptions, the 
parameter of interest and the resulting dynamic treatment regimen.  Section 4 discusses the 
dependence of the HA-MSM parameter on the observed treatment mechanism. Section 5 
presents an equality under which HA-MSM treatment rules are statically optimal (i.e. 
independent of the treatment mechanism) and gives a sufficient condition for the equality 
to hold. Section 6 shows how including in the HA-MSM model either: 1) the entire 
observed history, or 2) a summary of the history provided by the treatment mechanism, 
ensures this equality, and thus static optimality.  Section 7 uses Directed Acyclic Graph 
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theory to demonstrate that the necessary equality also holds under specific causal 
structures. Thus, in certain contexts, incorporation of the treatment mechanism may not be 
necessary. Section 8 presents examples of statically optimal treatment rules derived from 
the data example. The results illustrate the implementation of the treatment mechanism 
method to ensure static optimality, as well as a causal structure under which inclusion of 
the treatment mechanism as a covariate is not needed. Finally, we conclude with a 
discussion in Section 9, including a comparison of statically optimal regimens to the truly 
optimal dynamic regimes. 
 
2. HIV DATA EXAMPLE: WHEN TO SWITCH ANTIRETROVIRAL THERAPY?   
Combination antiretroviral therapy can successfully suppress viral replication in 
many HIV-infected individuals. As a result, the immune system recovers, CD4 T cell 
counts increase, and clinical prognosis improves dramatically [10].  Unfortunately, HIV 
frequently develops resistance to the drugs being used to treat it, allowing the virus to 
resume replication and resulting in an increase in the amount of virus in the patient’s blood 
(measured as plasma HIV RNA level or viral load). When this loss of virologic 
suppression occurs, clinicians are faced with an important treatment decision: how to 
decide when to modify the patient’s antiretroviral regimen. Waiting too long to switch to a 
new regimen may result in the accumulation of additional resistance mutations.  Also, 
increased levels of viral replication will lead over time to progressive loss of CD4+ T cell 
counts. However, switching regimens too early can deplete future treatment options, and 
may result in increased toxicity. (For a review of this issue, see Deeks [11].)   Importantly, 
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the decision as to “when to switch” is often made by clinicians based in part on the number 
of previous treatment regimens (with fewer prior regimens leading to a desire to modify 
therapy earlier), and the rate at which patients appear to be progressing clinically.  Hence, 
the optimal strategy for deciding when to switch is likely to be based on the evolution of 
patient and virologic characteristics over the course of non-suppressive therapy. 
 We used HA-MSM to estimate the effect of time until modifying antiretroviral 
therapy regimen on CD4 T cell count 8 months in the future. Data were drawn from the 
Study on the Consequences of the Protease Inhibitor Era (SCOPE) cohort, an observational 
cohort of HIV-infected individuals followed between 2000 and 2004 in San Francisco, 
California. Data were collected on socioeconomic status (housing, income, employment), 
antiretroviral medication use and adherence, occurrence of opportunistic infection and 
malignancy, recreational drug use, plasma HIV RNA levels, and CD4/CD8 T cell counts. 
Subjects qualified for the current analysis (t=0) if they experienced loss of virologic 
suppression on an antiretroviral regimen. Loss of virologic suppression (“virologic 
failure”) was defined using either of the following criteria: 1) at least two detectable viral 
loads, and no undetectable viral loads in a 4 month period while on a stable antiretroviral 
regimen; or, 2) at least two undetectable viral loads and no detectable viral loads within the 
first 6 months of starting a new regimen.   One hundred subjects experiencing a total of 
116 episodes of virologic failure were identified from the SCOPE cohort and contributed 
to the analyses described here.  For a full description of the sample, see [4]. 
The treatment of interest (time until modification of the antiretroviral regimen, or 
“switching”) was defined using a vector of binary covariates ))(),...,0(()( KAAKA = , 
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where 0 denoted the time virologic failure occurred, and K+1 denoted the end of follow 
up. A(t) remained equal to one as long as a patient remained on his original non-
suppressive therapy, jumped to zero as soon as a subject switched therapy, and remained 
zero thereafter. Longitudinal covariates measured on a subject were 
defined ))1(),...,0(()1( +=+ KLLKL , where L(t) was measured before A(t). The outcome 
of interest for a given time point j was CD4 T cell count m=8 months in the future 
(Y(j+m)). The observed data for a given subject thus consisted of ))1(),(( += KLKAO . 
 
3. REVIEW OF HA-MSM 
HA-MSM rely on the counterfactual framework for causal inference, under which 
each individual has a set of counterfactual covariate processes corresponding to the paths 
each covariate would have followed under each possible treatment history. This set of 
counterfactuals is the full data: ΑΑ∈+=   where),),1(( aKLX aFull denotes the set of 
possible treatment regimens, and )1( +KLa denotes the counterfactual covariates that 
would have been observed over the course of follow-up if an individual had followed 
treatment regimen )()( KaKA = . Using the counterfactual framework, a set of 
counterfactual CD4 T cell counts (and other covariates) existed for each individual under 
each possible switch time. 
Under the counterfactual framework, the observed covariate values for an 
individual are assumed to be equal to the individual’s counterfactual covariate values under 
her observed treatment history (the consistency assumption): 
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))1(),1(( ++= KLKAO A        (1) 
Under this assumption (1), the distribution of the observed data is indexed by 1) the 
distribution of the full data ( xF ), and 2) the distribution of the treatment history given the 
full data ( gXag Full =)|( ): gFXPO ,~ , where )|()|(
FullFull XaAPXag ==  is the 
treatment mechanism, which acts as a missingness variable. 
HA-MSM further assume the existence of no unmeasured confounders (the 
Sequential Randomization Assumption or SRA); 
 )(),1(|)( tLtAXtA Full −C , for Kt ,...,0=      (2) 
In the HIV application, the SRA assumes that no unmeasured variables affect the decision 
to switch as well as future CD4 T cell count. Under the SRA, the treatment mechanism can 
be written as: 
 ∏
=
−=
K
t
Full tAtLtAPXAg
0
))1(),(|)(()|(      (3) 
Standard MSM model the expectation (or some other parameter) of the 
counterfactual outcome, conditional on baseline covariates of interest: )|)(( VmYE a , where 
V denotes the values of effect modifiers of interest at baseline (t=0). HA-MSM can be 
understood as fitting a standard MSM at each time point during follow up, which models 
counterfactual outcomes indexed by treatment after that time point conditional on a subset 
of observed treatment and covariate history up till that time point. As an alternative to 
fitting a separate model at each time point, a common model can be fit across time points.  
Let )( ja denote a future treatment regimen beginning at time point j until the 
outcome is measured m time points later (a(j) =a(j),…,a(j+m-1)). In general, HA-MSM are 
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concerned with the counterfactual outcome under the observed treatment history up till 
time (j-1) and specified a future treatment regimen from time j until the outcome is 
measured: 
)()1(
)( jajAmjY −+ . HA-MSM model the mean (or some other parameter) of these 
counterfactuals, conditional on V(j), a subset of the observed past up till time j 
( ))1(),(()( −⊂ jAjLjV ): 
  )](|)([
)()1(
jVmjYE jajA −+       (4) 
Typically, ))(),1(()( jSjAjV −= , where )()( jLjS ⊂ denotes the covariates conditioned 
on, or effect modifiers of interest. 
We applied this method among individuals experiencing loss of virologic 
suppression to estimate the effect of future time until switching therapy on CD4 T cell 
count 8 months later among individuals who remained on their original therapy. These 
counterfactual outcomes were denoted
)()1(
)( jcjAmjY −+ , where c(j) denotes the 
counterfactual future time (after time j) until a subject either switches treatment or the 
outcome is measured at time j+m. Note that c(j) is a summary of the counterfactual 
treatment regimen beginning at time  j (i.e. c(j) is a summary of a(j)). HA-MSM were used 
to estimate the following history-adjusted mean: 
)](),1(|)([ )()1( jSjAmjYE jcjA −+ −     (5)  
Models were fit only among those individuals who had not already switched therapy 
( 1)1( =−jA ), and only among those individuals who had not experienced re-suppression 
of the virus while on the same therapy ( 0)( =jSup ). In two sets of analyses, the additional 
effect modifiers of interest were CD4 count at time j (CD4(j)), and the presence of an 
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opportunistic disease at time j (OD(j)). Thus ))(),(4()( jSupjCDjS = , and 
))(),(()( jSupjODjS = , in turn. In other words, among individuals who had not yet 
switched therapy or been re-suppressed by time point j, HA-MSM were used to model the 
mean counterfactual CD4 T cell counts that would have been observed if this entire 
subpopulation (or a random sample) had switched therapy c(j) months after time j, and 
how these expected counterfactual outcomes differed depending on time elapsed since loss 
of suppression occurred (j), and on either a patient’s CD4 T cell count at time j  (CD4(j)) 
or the presence of opportunistic disease (OD(j)) at time j.  
The HA-MSM parameter identifies an interesting dynamic treatment regimen, or 
rule for assigning treatment over time in response to individual changes in covariates. In 
the HIV analyses, the history-adjusted mean estimates, at each time point j, the effect of 
additional time until switching therapy on future CD4 T cell count among individuals who 
have not yet switched, conditional on covariates of interest. E.g., the effect of an additional 
month until switching is estimated as 
))(,1)1(|)(())(,1)1(|)(( )()1(1)()1( jSjAmjYEjSjAmjYE jcjAjcjA =−+−=−+ −+− .  
This suggests the following treatment rule: when additional time waiting to switch 
decreases expected future CD4 T cell count, switch immediately; when additional time 
waiting increases expected future CD4 T cell count, wait until the next time point to 
switch, and then reevaluate the estimated effect of additional waiting time. More generally, 
the treatment rule identified by HA-MSM consists of following, at each time point, the 
first action of the future static treatment plan that optimizes expected outcome. This 
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treatment plan is updated at each time point in response to changes in patient covariates. 
Thus the HA-MSM dynamic treatment rule can be defined as follows: 
)).(|( ofaction first   the torefers )1))((|( and 
, at timedecsion   treatment theis ))(|( where
 ),1))((|())(|(
))(),1()1(|)((maxarg))(|(
**
*
)()1(
)(
*
jVjajVja
jjVjd
jVjajVjd
jSjajAmjYEjVja jajA
ja
≡
−=−+≡
−
 
4. MOTIVATION FOR STATICALLY OPTIMAL TREATMENT RULES 
The history-adjusted mean (4) is a parameter of both the full data and the treatment 
mechanism in the observed data [3]. To see this, consider that assignment of treatment up 
to time j affects V(j) values at time j (i.e. membership in the subpopulations, or strata, of 
interest at time j). Thus, the observed treatment up till time j can affect the counterfactual 
mean within the strata of interest.   
In other words, if treatment up till time j had been assigned differently (for 
example, if treatment up till time j had been assigned randomly), members of a given 
subpopulation of interest at time j (individuals for whom V(j)=v(j)) would not necessarily 
be exchangeable with the corresponding subpopulation in the observed data. Specifically, 
the two groups would differ as a result of differences in the covariates used to assign 
treatment.  To the extent that these covariates also affect outcome, estimates of the effect 
of future treatment would also differ between the two groups.  As a result, the optimal 
future treatment plan identified for a given stratum of V(j) in the observed data can fail to 
optimize outcome if applied to the corresponding stratum in an experiment where 
treatment was assigned differently.  
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Thus, the dynamic treatment regime estimated by HA-MSM depends on the 
observed treatment mechanism; a treatment rule estimated from an observational cohort 
might not remain statically optimal if applied to an identical cohort with a different 
treatment mechanism. This is particularly troubling, in the sense that the rule itself is a 
treatment mechanism. Thus if a HA-MSM-derived treatment rule were applied to an 
identical population beginning at time 0 (the start of follow up), at later time points the rule 
might no longer continue to select the optimal treatment plan.  
For example, in the HIV analyses, HA-MSM were used to identify the best future 
treatment plan (switch immediately or wait to switch) among the subpopulation who had 
not yet switched therapy.   Membership in the subpopulation of individuals who remained 
on their non-suppressive therapy changed over time, as a result of the process for deciding 
when to switch therapy (the treatment mechanism). Specifically, the treatment mechanism 
revealed that individuals were more likely to switch therapy if they had lower CD4 T cell 
counts. As a result, the population that remained on non-suppressive therapy at a given 
time point, among whom the best future treatment plan was estimated, contained a 
disproportionate number of individuals who had maintained high CD4 T cell counts. 
The subpopulation that remained on non-suppressive therapy over time would have 
differed if the decision process for switching treatment had differed. For example, if 
treatment had been assigned randomly, the subpopulation remaining on non-suppressive 
therapy at a given time point would have included more individuals with low prior CD4 T 
cell counts. To the extent that past CD4 T cell count affects future CD4 T cell count, the 
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expected future CD4 T cell count would differ would differ between the two 
subpopulations, and thus the optimal treatment decision could differ.  
In other words, since membership in a given stratum of interest can depend on the 
way that treatment was assigned, the effect of future treatment decisions and thus the 
optimal treatment plan for the stratum can depend on the observed treatment mechanism. 
Our goal, however, is to identify stratum-specific future treatment plans that are expected 
to optimize future outcome regardless of the way in which past treatment was assigned. 
The resulting statically optimal individualized treatment rules will then continue to identify 
the optimal future plan at each time point if applied to a comparable population beginning 
at any time point during follow up.  For example, a statically optimal rule for deciding 
when to switch therapy would choose the best treatment plan (switch or not) among people 
remaining on their non-suppressive regimen at a given time point, regardless of how the 
decision to switch was made up till that time point. Thus a statically optimal rule will 
identify the optimal treatment plan at each time point if applied in the context of a clinical 
trial (where the rule of interest has been applied since time 0), or alternatively, if applied in 
the context of clinical practice (where some other decision process has been applied since 
time 0). 
 
5. STATICALLY OPTIMAL TREATMENT RULES 
 HA-MSM identify statically optimal individualized treatment rules when the 
history-adjusted mean no longer depends on the observed treatment history, or in other 
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words, when the observed history-adjusted mean equals the counterfactual history-adjusted 
mean: 
 ))(|)(())(),1()1(|)((
)1()()1()()1( −−−
+=−=−+ jajajajajA jSmjYEjSjajAmjYE . (6) 
When equality (6) holds, then the optimal future treatment plan at each time point j 
estimated by HA-MSM will be the same as the optimal future treatment plan at each time 
point j under any fixed treatment history up till that time point:  
))(|)((maxarg
))(),1()1(|)((maxarg))(|(
)1()()1(
)(
)()1(
)(
*
−−
−
+=
−=−+≡
jajaja
ja
jajA
ja
jSmjYE
jSjajAmjYEjVja
 
Note that, given the covariates on which the statically optimal rule is based ( )( jS ), the 
treatment history that corresponds to following the statically optimal rule itself is simply 
one of these possible fixed treatment histories (given )( jS , the statically optimal rule 
deterministically assigns a treatment a(t), t=0,…,j-1). Thus, when equality (6) holds, then 
the optimal future treatment plan at a given time point estimated by HA-MSM will indeed 
identify the optimal future treatment plan if the study population had been following the 
statically optimal rule (or any other treatment mechanism) up till that time point.  
The following Theorem presents an equality that is sufficient for identity (6) to 
hold, and thus to ensure that the rules estimated by HA-MSM are statically optimal.  
 
Theorem 1.  
If   
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP
aaa
=−=−==+=+−=−  (7) 
Hosted by The Berkeley Electronic Press
 14
then ))(|)(())(),1()1(|)((
)1()()1()()1( −−−
+=−=−+ jajajajajA jSmjYEjSjajAmjYE  and 
the HA-MSM derived rule is statically optimal. 
 
The proof of Theorem 1 is presented in Appendix 1. Here, we present the intuition behind 
the theorem, which further provides insight into the conditions, discussed below, for the 
identity (7) to hold. 
Non-identity between the observed history-adjusted mean and the counterfactual 
history-adjusted mean can be seen as a problem of confounding. Consider the case where 
the goal is to estimate a simple counterfactual mean under treatment history a : )( aYE . 
Clearly, unless the entire study population, or a random sample, received treatment 
history a , )( aYE  is not necessarily equal to the mean outcome among people who received 
treatment history a  in the observed data ( )|()( aAYEYE Aa =≠ ). This is a classic example 
of confounding; the two parameters will differ to the extent there are covariates that affect 
both treatment assignment and outcome, making treatment assignment dependent on 
counterfactual outcome ( )()|( aAPYaAP a =≠= ). Next, consider the case where the goal 
is to estimate a counterfactual mean under treatment history a , given baseline covariates of 
interest S: )|( SYE a . We say that S is sufficient to control for confounding if, once we 
condition on S, treatment assignment no longer depends on counterfactual outcome (within 
strata of S, treatment is randomized): )|(),|( SaAPYSaAP a === . In this case, within 
strata of S, the mean outcome among people who received treatment history a  in the 
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observed data is equivalent to the mean counterfactual outcome under treatment a : 
)|(),|( SYESaAYE aA == . This concept is the motivation for the use of multivariable 
regression for causal inference. 
The same concept can be extended to the current situation, only now only 
considering the equivalence of mean outcomes indexed by observed vs. counterfactual 
treatment through time j-1. In order for equality (6) to hold, the covariates of interest 
)( jS must be sufficient to control for confounding of treatment assignment through time   
j-1 ( )1( −jA )on counterfactual outcome 
)()1( jajAY − . In other words, if treatment assignment 
through time j-1 is independent of counterfactual outcome, given covariates of interest 
(equality (7)), then the counterfactual history-adjusted mean will equal the observed 
history-adjusted mean (equality (6)). 
If equality (7) holds, then the HA-MSM parameter is no longer dependent on the 
treatment mechanism. In the following two sections, we discuss choices of )( jS sufficient 
for equality (7) to hold, and thus sufficient to ensure that the HA-MSM individualized 
treatment rule is statically optimal. 
  
6. INCORPORATING COVARIATE HISTORY TO ENSURE STATIC 
OPTIMALITY. 
 As we show in this section, inclusion in )( jS of either the entire covariate history 
up to time (j-1), or a particular summary of the covariates that affect treatment assignment 
up till time (j-1), is sufficient for equality (7) to hold. The intuitive motivation for this 
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approach again relies on confounding. We know from Section 5 that if )( jS is sufficient to 
control for confounding of )1( −jA  on counterfactual outcome
)()1( jajAY − , then equality (7) 
will hold. We further know that confounding arises as a result of covariates that affect both 
treatment assignment and outcome. Thus, by including in )( jS  all covariates that affect 
treatment assignment, we ensure that the HA-MSM-derived treatment rules are statically 
optimal. We present this result as a Lemma, below (the proof is provided in Appendix 2). 
 
Lemma 1.  
 If )|)1()1(( xXjajAP Full =−=−  is only a function of aa jSjS )()1( ⊂− , then 
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP aaa =−=−==+=+−=−
 
and (by Theorem 1)  the HA-MSM parameter is statically optimal.  
 
Several choices of )( jS  are sufficient to ensure that 
)|)1()1(( xXjajAP Full =−=−  is only a function of aa jSjS )()1( ⊂− , and thus that the 
HA-MSM individualized treatment rules are statically optimal. For example, this is true if 
the HA-MSM parameter conditions on the entire covariate history in addition to any effect 
modifiers of interest. Under the SRA (2), ))1(),(()( −= jAjSjV  then includes all 
covariates which affect treatment assignment up till time j.  
Sufficient Condition 1: ( ))(*),1(()( jSjLjS −= ,  
where )(* jS  denotes the effect modifiers of interest 
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 Including the entire covariate history in the HA-MSM model removes the 
dependency of the resulting parameter on the treatment mechanism. However, when 
several covariates are measured over multiple time points, the covariate history )( jL can 
become very high dimensional. Specifying a reasonable HA-MSM model for 
)](|)([
)()1(
jVmjYE jajA −+  can thus become challenging or unfeasible.  
An alternative to conditioning on the entire covariate history is to condition only 
those covariates that affect treatment assignment up till time (j-1).   The covariates 
affecting treatment assignment can be summarized by including the treatment mechanism 
itself (through time j-1) as a covariate in )( jS : 
Sufficient Condition 2: ))(*),|)1((()( jSXjAgjS Full−= ,  
where )(* jS  denotes the effect modifiers of interest 
When the treatment mechanism interacts with the exposure of interest, the optimal 
future treatment plan at time j will depend on the treatment mechanism up till time j in 
addition to other covariates of interest. In this setting, implementing the resulting rule in 
practice will require measuring not only the effect modifiers of interest, but also all other 
covariates that contribute to the treatment mechanism. 
 
7. CAUSAL STRUCTURES SUFFICIENT TO ENSURE STATIC OPTIMALITY 
 The previous section showed how conditioning the HA-MSM parameter on 
covariate history in addition to effect modifiers of interest can remove dependency on the 
observed treatment assignment and permit estimation of a statically optimal treatment rule. 
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Both approaches presented rely, however, on adjusting for all covariates that affect 
treatment assignment. In contrast, Pearl’s causal graph theory [12] provides a tool for 
identifying a minimal set of covariates sufficient to control for confounding. In this 
section, we apply d-separation from DAG methodology to introduce an alternative 
condition for )( jS  sufficient to ensure static optimality of the HA-MSM parameter. 
Specifically, we show that, under certain causal structures, )( jS  need not include 
covariate history (either in its entirety or summarized based on the treatment mechanism) 
to ensure the static optimality of the treatment rule estimated. These results introduce 
greater flexibility in the choice of sufficient )( jS , and provide a graphical tool to identify 
sufficient alternatives.  
Pearl defines the graphical criteria for d-separation as follows (Definition 1.2.3): 
Definition of d-separation: 
“A path p is said to be d-separated (or blocked) by a set of nodes Z if and only if  
1. p contains a chain jmi →→  or a fork jmi →←  such that the middle node 
m is in Z, or 
2. p contains an inverted fork (or collider) jmi ←→  such that the middle node m 
is not in Z and such that no descendent of m is in Z 
A set Z is said to d-separate X from Y if and only if Z blocks every path from a node in X to 
a node in Y.” 
 
Pearl shows (Theorem 1.2.4) that “If sets X and Y are d-separated by Z in a DAG 
G, then X is independent of Y conditional on Z in every distribution compatible with G”.  
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Thus, d-separation of X and Y by Z (written GZYX )|( C ) implies that X is conditionally 
independent of Y given Z (written PZYX )|( C ), and thus 
that )|(),|( zZxXPzZyYxXP ====== . This theorem provides us with a graphical 
criterion (presented as a Lemma) for evaluating the sufficiency of )( jS  for equality (7) to 
hold.  
 
Lemma 2. If )( jS a d-separates )1( −jA  from amjY )( + ,  then )( jS is sufficient to ensure 
that 
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP aaa =−=−==+=+−=−
and thus (by Theorem 1)  that the HA-MSM parameter is statically optimal.  
 
In applying the graphical criterion of d-separation, a DAG must first be converted 
from a graph showing causal relationships in the observed data, to a graph showing causal 
relations between the observed treatment and the counterfactual covariate processes. This 
process in involves two steps (Figure 1). First, replace the observed covariates )1( +KL  by 
their counterfactual counterparts aKL )1( + . Second, erase all arrows from )(KA to 
aKL )1( +  (the observed treatment does not affect the counterfactual values of covariates 
under a specified treatment). The resulting causal graph (Figure 1b) now shows the causal 
relations between the observed treatment history and the counterfactual values of 
covariates if treatment history had been set at a .  
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The d-separation criterion of Lemma 2 suggests an alternative graph-based proof to 
Lemma 1. In the causal graph corresponding to the observed treatment history and 
counterfactual covariate values (Figure 1b), all paths from treatment )(KA  to 
counterfactual covariates aKL )1( + are deleted. Thus, the only possible paths connecting 
)1( −jA to amjY )( +  are “backdoor paths” (i.e. paths from )1( −jA  to amjY )( +  via 
arrows into )1( −jA ). Graphically, Lemma 1 states that )( jS  is sufficient for equality (7) 
and hence static optimality to hold if aa jSjS )()1( ⊂−  includes all covariates with causal 
arrows into )1( −jA . But if )( jS a  includes all covariates with arrows into )1( −jA , then 
)( jS a  must block all backdoor paths, and thus all paths, from )1( −jA  to amjY )( + , and 
thus ensure their d-separation. As result, by Lemma 2, equation (7) must hold and )( jS is 
sufficient to ensure static optimality.  
The graphical criterion of d-separation provides a minimal condition for )( jS to be 
sufficient. As shown, if ajS )(  includes all covariates with causal arrows into )1( −jA  (as 
required by Lemma 1), then d-separation holds. In addition, d-separation holds under 
many causal structures where ajS )(  does not include all covariates with causal arrows 
into )1( −jA , and thus where neither Sufficient Conditions 1 nor 2 are met (Figure 2). 
Given a DAG, Lemma 2 provides a graphical tool for suggesting alternative 
choices of )( jS , and for evaluating their sufficiency.  Figures 2 and 3 present several 
sample causal graphs, illustrating examples of )( jS sufficient and insufficient to ensure 
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static optimality. Note, however, that the sufficiency of a particular choice of )( jS , other 
than a choice fulfilling Lemma 1, will depend on the specific causal structure of the data. 
Specifying this causal structure becomes more challenging as the number of covariates and 
time points increases. 
 
8. RESULTS: STATICALLY OPTIMAL TREATMENT RULES FOR DECIDING 
WHEN TO SWITCH THERAPY 
 Two sets of analyses were performed, aimed at estimating rules among individuals 
who had not been re-suppressed based on two covariates of interest, CD4 T cell count at 
time j and diagnosis with an opportunistic disease at time j 
( ))(4,0)(()(* jCDjSupjS == , and ))(,0)(()(* jODjSupjS == , respectively). All HA-
MSM models were fit using the inverse probability of treatment weighted estimator [3, 4]. 
The treatment mechanism (probability of switching given the past) was fit data-adaptively 
using the Deletion/Substitution/Addition algorithm and 5-fold cross validation [13]. 
Confidence intervals for model coefficients are based on 100 non-parametric bootstrap 
samples. 
 
Analyses 1: Treatment Rules Based on Opportunistic Disease 
In the first set of analyses, we first estimated an individualized treatment rule based 
on the following model (Model 1), which estimates the effect of additional time until 
switching therapy c(j) on future CD4 T cell count among individuals who have not yet 
switched therapy ( 1)1( =−jA ) or been re-suppressed (Sup(j)=0), given elapsed time since 
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virologic failure occurred  (j) and current diagnosis with an AIDS-defining opportunistic 
disease (OD(j)): 
 
)()()()()(
))(,0)(,1)1(|)((
543210
)()1(
jcjODjODjcjjjc
jODjSupjAmjYE jcjA
×++×+++
===−+
−
ββββββ  
The corresponding estimate of the effect of waiting to switch (Table 1) yielded the 
following treatment rule: In individuals with a current diagnosis of an opportunistic 
disease, stay on the same therapy and re-evaluate the following month. In individuals 
without such a diagnosis, switch therapy immediately if less than 8 months have elapsed 
since loss of suppression occurred, otherwise wait to switch. 
In the absence of an explicit causal structure, there is no guarantee that this 
treatment rule would continue to optimize outcome if it were applied to an identical 
population, beginning when loss of suppression occurred. In order to estimate a statically 
optimal treatment rule, the treatment mechanism through time j-1 was incorporated into the 
HA-MSM model (Model 2): 
 
))(),1(|)(()()()()()(
))(,0)(,1)1(|)((
1
0
6543210
)()1(
lLlAlAgjcjODjODjcjjjc
jODjSupjAmjYE
j
l
jcjA
−+×++×+++
===−+
∏
−
=
−
βββββββ  
(Alternatively, the treatment mechanism could have been incorporated as an interaction 
with the exposure of interest (c(j)) and/or the other covariates. However, we found no 
evidence of interactions between the treatment mechanism and time until switching 
therapy.) The estimated statically optimal rule for deciding when to switch given current 
opportunistic disease and elapsed time (Table 2), states that, regardless of diagnosis of with 
opportunistic disease and time elapsed since loss of suppression occurred, treatment should 
http://biostats.bepress.com/ucbbiostat/paper207
 23
be switched immediately. The latter rule, rather than the former, would be expected to 
optimize patient outcome if applied to a comparable population in a clinical trial. In fact, 
such a rule makes more clinical sense than the former, non-statically optimal, rule in that 
waiting to switch therapy is unlikely to be more beneficial among those who have a current 
opportunistic disease. 
 
Analyses 2: Treatment Rules Based on CD4 T Cell Count 
 In the second set of analyses, we estimated an individualized treatment rule based 
on the estimated effect of future time until switching (c(j)) on future CD4 T cell count 
among individuals who had not yet switched therapy or been re-suppressed,  given current 
CD4 T cell count (CD4(j)) and elapsed time (j) (Table 3).  This effect was estimated using 
the following HA-MSM (Model 3): 
jjCDjcjjCDjjcjCDjcjjCD
jcjCDjSupjAmjYE jcjA
××+×+×+×+++
+===−+
−
)(4)()(4)()(4)()(4
)())(4,0)(,1)1(|)((
765432
10)()1(
ββββββ
ββ
 
To estimate a statically optimal individualized treatment rule, we then fit an 
additional HA-MSM, now including the treatment mechanism as a covariate.  Again, after 
considering potential multi-way interactions, our final HA-MSM model included the 
treatment mechanism as a main term only (Model 4): 
∏
−
=
−
−+××+×+×+×
++++===−+
1
0
87654
3210)()1(
))(),1(|)(()(4)()(4)()(4)(
)(4)())(4,0)(,1)1(|)((
j
l
jcjA
lLlAlAgjjCDjcjjCDjjcjCDjc
jjCDjcjCDjSupjAmjYE
βββββ
ββββ
The resulting effect estimates yielded the following statically optimal treatment rule (Table 
4): 
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( )[ ]
j at timeWait :0
j at timeSwitch  :1
0)(4009.02.1)(405.00.9
=
=
<××−×+×+−=
j
j
j
d
d
jjCDjjCDId
 
In other words, when the expected effect of waiting to switch is negative, switch the 
patient immediately; when the expected effect is positive, wait to switch and re-evaluate at 
the subsequent visit. 
 95% confidence intervals for each of the coefficients in this rule, based on 100 non-
parametric bootstrap samples, are presented in Table 4. Alternatively, bootstrap re-
sampling can be used to estimate variability in the treatment decision itself by plotting the 
proportion of bootstrap samples in which the statically optimal treatment rule indicates a 
switch for a range of CD4 T cell counts and elapsed times since loss of suppression. Such 
an analysis (Figure 4) suggests that, early after loss of suppression occurs, there is strong 
evidence that patients with low CD4 T cell count should be switched to a new regimen, 
while patients with high CD4 T-cell counts can afford to wait. In contrast, among patients 
who have already spent 5 months on non-suppressive therapy, variability in the decision to 
switch depends less on current CD4 T cell count, suggesting that the decision to switch for 
these patients should perhaps be based on other factors.  
Interestingly, the initial HA-MSM fit (Model 3), which included only current CD4 
T cell count and elapsed time, and the HA-MSM also adjusting for the treatment 
mechanism (Model 4) provided very similar estimates of the effect of future time until 
switching and the modification of this effect by current CD4 T cell count and elapsed time 
(Table 3 vs. Table 4, respectively). As a result, the two approaches yielded very similar 
individualized treatment rules. The small change in coefficients in the CD4 T cell –based 
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treatment rule after adjusting for the treatment mechanism can be explained by the 
postulated causal structure of the data (Figure 5).  This DAG also illustrates why the 
opportunistic disease-based treatment rule was altered by incorporation of the treatment 
mechanism.  In this DAG, CD4 T cell count at time j, but not opportunistic disease 
diagnosis at time j, is sufficient to d-separate treatment history prior to time j from CD4 T 
cell count m months in the future.  
 
9. DISCUSSION 
As mentioned in the introduction, the history-adjusted statically optimal treatment 
rules discussed in this paper must be differentiated from the optimal dynamic treatment 
regimes, as estimated by Murphy, et. al. [1-3].  A statically optimal rule assigns a patient 
the first action of the future static treatment plan that will optimize his or her expected 
outcome, given the patient’s covariates. The plan can then be updated at subsequent time 
points in response to changes in patient covariates. In contrast, an optimal dynamic regime 
selects, at a single point in time, the future rule that will optimize expected outcome at a 
fixed point in the future. Thus the statically optimal rule selects between different static 
plans, and then updates this selection at subsequent time points, while the optimal dynamic 
regime selects among candidate rules at a single time point.  
The two approaches estimate dynamic rules under very different models. There are 
clearly scenarios where the statically optimal rule results in an inferior expected outcome 
than the optimal dynamic regime; a simulation illustrating such a scenario is given in [3] . 
However, in essentially all cases, the models on which both approaches are based will be 
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incorrectly specified. Future research is needed on the relative performance of the two 
types of estimated rules in such settings.   
The statically optimal rule does offer several practical advantages. Unlike the truly 
optimal dynamic rule, the statically optimal rule can be estimated using standard software. 
In addition, the statically optimal rule provides increased flexibility in the outcome that is 
optimized. The optimal dynamic rule optimizes outcome at a fixed time point, while the 
statically optimal rule can optimize outcome either at a fixed or moving time point. In 
many clinical settings, the latter type of outcome is of greater clinical interest. For 
example, the goal of the clinician in managing resistant HIV is to continually maintain 
future CD4 T cell count (and patient health); thus, as the patient is followed over time, the 
interval over which the clinician aims to optimize outcome continually shifts forward. 
In summary, HA-MSM estimate modification of causal effects by time-varying 
variables, and thus can be used to identify individualized treatment rules for modifying 
treatment in response to a patient’s changing covariates.  However, the dependence of the 
HA-MSM parameter on the observed treatment mechanism, or the way in which the 
assignment of treatment at each time point depended on a subject’s past, means that such 
rules would not necessarily remain statically optimal if applied in a clinical trial. As we 
have illustrated, treatment rules which are truly statically optimal, or in other words, which 
no longer depend on the treatment mechanism, can be estimated using HA-MSM given 
that the covariates on which the rule depends are sufficient to control for confounding of 
the effect of past treatment on outcome. As a result, by selecting the correct covariates, 
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HA-MSM can be applied to observational data to identify individualized treatment rules 
appropriate for evaluation in a clinical trial, or for use in clinical practice.  
Causal graphs can be used to identify whether a candidate set of covariates is 
sufficient to control confounding and thus ensure static optimality, as well as to suggest 
alternative sets of sufficient covariates. This approach does not rely on consistent 
estimation of the treatment mechanism, thus the Double Robust HA-MSM estimator [3] 
will remain consistent if either the treatment mechanism or data-generating distribution are 
correctly estimated. This approach does, however, rely on use of a DAG that accurately 
represents the causal relations in the data, and thus relies heavily of the background 
knowledge of the researcher. As Figure 4 illustrates, the causal relationships in 
longitudinal data are often complex, and their correct specification may be unpractical. 
Inclusion of the entire covariate history, or alternatively, of the treatment 
mechanism in the HA-MSM model also ensures static optimality, regardless of the specific 
causal context. Under this approach, the static optimality of the dynamic treatment rule 
depends on consistent estimation of the treatment mechanism. As a result, the Double 
Robust HA-MSM estimator [3] will not protect against misspecification of the treatment 
mechanism when deriving candidate treatment rules, although it may provide gains in 
efficiency. However, the treatment mechanism-based approach has the advantage of 
generally requiring a much lower dimensional HA-MSM model than the approach which 
adjusts for the entire covariate history. The reliance of the former approach on consistent 
estimation of the treatment mechanism also implies that in settings where the treatment 
mechanism is known (such as in the context of sequentially randomized trials) HA-MSM 
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can estimate statically optimal treatment rules without any assumptions beyond the HA-
MSM model itself. 
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FIGURE 1. Illustration of DAG manipulation required prior to evaluation of d-separation 
to test whether a given )( jS  is sufficient to ensure static optimality1. 
 
 
                                                 
1 Figure 1 presents one possible basic causal structure for longitudinal data. To improve the simplicity of the 
graphs involved, we present the situation where j=2, K=3, and Y(j+m)=Y(j+2). Similar reasoning can be 
used for larger j, K and m. 
A(j-2) A(j-1) A(j) A(j+1) 
A. Causal relationships in the observed data. 
L(j-2) L(j-1) L(j) L(j+1) 
amjY )( +
A(j-2) A(j-1) A(j) A(j+1) 
)2( −jLa  )1( −jLa )( jLa )1( +jLa amjY )( +
B. Causal relationships between observed treatment and counterfactual 
covariates. 
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FIGURE 2. DAG-based examples of )( jS sufficient to d-separate )1( −jA  from 
amjY )( +  in specific causal settings.
1  
                                                 
1To simplify presentation, we use j=2, K=3, and Y(j+m)=Y(j+1), and covariates and treatment occurring 
after time j are not shown..  
A. Example 1.  )()(  aa jLjS =  
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa )( jSa amjY )( +
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa  )( jSa amjY )( +
B. Example 2. ))(,)(()( aaa jCjSjL =  
)( jCa
C. Example 3. ))(,)(()( aaa jCjSjL =  
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa  )( jCa amjY )( +)( jSa
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FIGURE 3. DAG-based examples of )( jS not sufficient to d-separate )1( −jA  from 
amjY )( +  in specific causal settings.
1  
 
                                                 
1 To simplify presentation, we use j=2, K=3, and Y(j+m)=Y(j+1), and covariates and treatment occurring 
after time j are not shown. 
A. Example 1. )( )(
 
jSjL
aa
=  
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa )( jSa amjY )( +
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa )( jCa amjY )( +
B. Example 2. ))(,)(()( aaa jCjSjL =  
)( jSa
A(j-2) A(j-1) A(j)
)2( −jLa  )1( −jLa  amjY )( +)( jSa
U
C. Example 3. )( )(
 
jSjL
aa
= . U not measured.
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FIGURE 4. Variability in treatment decision indicated by statically optimal treatment rule, 
according to CD4 T cell count and elapsed time since loss of suppression occurred. 
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FIGURE 5. Proposed DAG for HIV data example. )(4)( jCDjS = , but not )()( jODjS = , 
sufficient for static optimality. Similarly, CD4(t), but not OD(t) (t=0,…K),  sufficient to 
control for confounding1.  
                                                 
1 To simplify presentation, we use j=2, K=3, and Y(j+m)=Y(j+2).  
)(* jL
a
= additional components of the treatment mechanism (e.g. adherence) 
 
A(j-2) A(j-1) A(j)
)2(4 −jCD a  )1(4 −jCD a
)( jOD
a
amjY )( +
)(4 jCD a
)2( −jODa  )1( −jODa
)1(4 +jCD
a
)1( +jOD
a
A(j+1) 
)(* jL
a)2(* −jL a  )1(* −jL a )1(* +jL a  
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TABLE 1. Individualized treatment rule for analysis 1, based on Model 1 (without 
treatment mechanism as covariate)  
Coefficient  95% CI1 2
 
β1 = -4.0 
β3 = 0.56  x j  
β5 = 6.4 x OD(j) 
-15.1, 7.1
-1.9, 3.1
-12.4, 25.2
 
Treatment Rule: 
( )[ ]
j at timeWait :0
j at timeSwitch  :1
0)(531
=
=
<×+×+=
j
j
j
d
d
jODjId βββ
 
 
 
                                                 
1 Based on 100 Bootstrap samples 
2 CI = Confidence Interval 
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TABLE 2. Individualized treatment rule for analysis 1, based on Model 2 (incorporating 
treatment mechanism as covariate)  
Coefficient  95% CI1 2
 
β1 = -2.6 
β3 = -0.28 x j  
β5 = 0.83 x OD(j) 
-13.1, 7.9
-2.3, 1.8
-15.7, 17.2
  
Treatment Rule: 
( )[ ]
j at timeWait :0
j at timeSwitch  :1
0)(531
=
=
<×+×+=
j
j
j
d
d
jODjId βββ
 
                                                 
1 Based on 100 Bootstrap samples 
2 CI = Confidence Interval 
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TABLE 3. Individualized treatment rule for analysis 2, based on Model 3 (without 
treatment mechanism as covariate) 
Coefficient  95% CI1 2
 
β1 =-9.2 
β4 =0.05 x CD4(j)  
β5 =1.5  x j  
β7 = - 0.009 x  CD4(j) x j 
-17.6, -7.6
0.02, 0.08
-0.4, 3.4
-0.02, -0.004
  
Treatment Rule: 
( )[ ]
j at timeWait :0
j at timeSwitch  :1
0)(4)(4 7541
=
=
<××+×+×+=
j
j
j
d
d
jjCDjjCDId ββββ
 
 
 
                                                 
1 Based on 100 Bootstrap samples 
2 CI = Confidence Interval 
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TABLE 4. Individualized treatment rule based on Model 4 (incorporating treatment 
mechanism as covariate) 
Coefficient  95% CI1 2
 
β1 = -9.0  
β4 = 0.05 x CD4(j)  
β5 = 1.2  x j  
β7 = - 0.009 x  CD4(j) x j 
-17.5, -0.5
0.02, 0.08
-0.7, 3.1
-0.02, -0.003
  
Treatment Rule: 
( )[ ]
j at timeWait :0
j at timeSwitch  :1
0)(4)(4 7541
=
=
<××+×+×+=
j
j
j
d
d
jjCDjjCDId ββββ
                                                 
1 Based on 100 Bootstrap samples 
2 CI = Confidence Interval 
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APPENDIX 1: Proof of Theorem 1- equality sufficient to ensure that HA-MSM estimate 
statically optimal treatment rules. 
Theorem 1.  
If   
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP aaa =−=−==+=+−=−  (7) 
then ))(|)(())(),1()1(|)(( )1()()1()()1( −−− +=−=−+ jajajajajA jSmjYEjSjajAmjYE . 
 
Proof:  
Note that 
∑ =−=−+=++=
=−=−+=
=−=−+
−
y
aa
aa
jajA
jsjSjajAmjymjYPmjy
jsjSjajAmjYE
jsjSjajAmjYE
))()(),1()1(|)()(()(
))()(),1()1(|)((
))()(),1()1(|)((
)()1(
 
and  
)()(())()(|)1()1((
))()(),()(())()(),()(|)1()1((
))()(),1()1((
))()(),1()1(),()((
))()(),1()1(|)()((
jsjSPjsjSjajAP
jsjSmjymjYPjsjSmjymjYjajAP
jsjSjajAP
jsjSjajAmjymjYP
jsjSjajAmjymjYP
aa
aaaa
a
aa
aa
==−=−
=+=+=+=+−=−
=
=−=−
=−=−+=+
=
=−=−+=+
 
Now note that  
))()((
)()(),()((
jsjSP
jsjSmjymjYP
a
aa
=
=+=+
 is only an FX parameter (i.e. a 
parameter of the Full Data), so it remains to show that the ratio 
http://biostats.bepress.com/ucbbiostat/paper207
 41
))()(|)1()1((
))()(),()(|)1()1((
jsjSjajAP
jsjSmjymjYjajAP
a
aa
=−=−
=+=+−=−
 does not depend on g. 
Specifically, if this ratio =1, or 
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP aaa =−=−==+=+−=−
 then this is true. 
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APPENDIX 2: Proof of Lemma 1- sufficient condition for equality (7) to hold, and thus 
for HA-MSM to estimate statically optimal treatment rules. 
Lemma 1.  
 If )|)1()1(( xXjajAP Full =−=−  is only a function of aa jSjS )()1( ⊂− , then 
))()(|)1()1(())()(),()(|)1()1(( jsjSjajAPjsjSmjymjYjajAP aaa =−=−==+=+−=−
 
and (by Theorem 1)  the HA-MSM parameter is statically optimal.  
 
Proof: 
Note that ),|),,|((),|( SYSYXPESYP ⋅=⋅ , so 
)))()(),()(|)),()(),()(|)1()1(((
))()(),()(|)1()1((
jsjSmjymjYxXjsjSmjymjYjajAPE
jsjSmjymjYjajAP
aa
Full
aa
aa
=+=+==+=+−=−=
=+=+−=−
  
Since  )( and )( aa jSmjY + are included in
FullX ,  
)|)1()1((),)(),()(|)1()1(( xXjajAPxXsjSmjymjYjajAP FullFull
aa
=−=−===+=+−=−
 
which is the treatment mechanism up till time (j-1). 
So, 
)))()(),()(|()|)1()1((
))()(),()(|)|)1()1(((
))()(),()(|)1()1((
jsjSmjymjYxXPxXjajAP
jsjSmjymjYxXjajAPE
jsjSmjymjYjajAP
aa
Full
x
Full
aa
Full
aa
=+=+==−=−=
=+=+=−=−=
=+=+−=−
∑
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If now ajS )(  is such that the treatment probability )|)1()1(( xXjajAP
Full
=−=−  is 
only a function of aa jSjS )()1( ⊂−  then it follows that, given 
)()(),()( jsjSmjymjY aa =+=+ , )|)1()1(( xXjajAP
Full
=−=−  is a constant, and thus 
)|)1()1((
))()(),()(|()|)1()1((
)))()(),()(|()|)1()1((
xXjajAP
jsjSmjymjYxXPxXjajAP
jsjSmjymjYxXPxXjajAP
Full
x
aa
FullFull
aa
Full
x
Full
=−=−=
=+=+==−=−=
=+=+==−=−
∑
∑
 
The same approach to the right hand side shows the two are equal and completes the proof. 
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